profit from every $100 of sales.
$0$100
Teleflex
$155.10+1.27% today
+41.7% in 1 year
1-year low $100.341-year high $156.33
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Teleflex sold, what it kept, and what it did with the cash.
Sales went from $2.79 billion in 2022 to $1.99 billion in 2025, with -$906 million of profit last year.
SalesProfit
Teleflex handed back more cash to shareholders than it generated last year.
Buybacks $300M
Free cash flow 2025$245M
Bought back its own shares$300M
Paid as dividends$60M
Cash vs. debt$379M vs. $2.7B
Teleflex vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Teleflex | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Teleflex's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,537 | 2,810 | 2,791 | 1,712 | 1,700 | 1,993 | |
| 1,325 | 1,550 | 1,531 | 1,040 | 1,037 | 1,121 | |
| – | – | 514 | 304 | 254 | 256 | |
| 651 | 854 | 731 | 419 | 271 | 303 | |
| 335 | 485 | 363 | 356 | 70 | -906 | |
| 7.09 | 10.23 | 7.68 | 7.53 | 1.48 | -20.30 | |
| 52.2% | 55.2% | 54.9% | 60.7% | 61.0% | 56.2% | |
| – | – | 18.4% | 17.7% | 14.9% | 12.8% | |
| 13.2% | 17.3% | 13.0% | 20.8% | 4.1% | -45.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 7,153 | 6,872 | 6,928 | 7,533 | 7,098 | 6,947 |
| Cash | 376 | 445 | 292 | 223 | 248 | 379 |
| Total debt | 2,587 | 1,988 | 1,832 | 1,926 | 1,744 | 2,726 |
| Total liabilities | 3,816 | 3,117 | 2,906 | 3,092 | 2,820 | 3,822 |
| 3,336 | 3,755 | 4,022 | 4,441 | 4,278 | 3,125 | |
| 47 | 47 | 47 | 47 | 47 | 45 | |
| 5.7% | 8.5% | 6.8% | 3.4% | 1.4% | 1.7% | |
| 10.1% | 12.9% | 9.0% | 8.0% | 1.6% | -29.0% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | 342 | 511 | 636 | 341 | |
| 91 | 72 | 79 | 46 | 90 | 95 | |
| – | – | 263 | 464 | 545 | 245 | |
| Dividends paid | 63 | 64 | 64 | 64 | 64 | 60 |
| – | – | 0 | 0 | 200 | 300 | |
| 21 | 23 | 27 | 27 | 26 | 26 |
Valuation
- –
- 23.1×
- –
- 1.9×
- 3.1×
- 25.1×
- 28.1×
- 4.0%
- -14.7%
- 1.0%
Profitability
- 56.2%
- 12.8%
- -45.4%
- -3.1%
- 2.7%
- 1.2%
- -28.3%
- -14.9%
- 3.0%
- 6.7%
Growth
- −4.7%
- –
- −51.8%
- +0.0%
- −1.2%
Financial health
- 1.6×
- 0.06
- 2.5%
- 1.6×
- 2.55
- 2.03
- 0.41
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 39%of 952
Top 41%of 884
Bottom 11%of 886
Top 28%of 987
What analysts expect
- Average price target
- $132.20
- Range
- $116.00 – $147.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 1.39 | 1.21 | +14.9% |
| Feb 26, 2026 | 1.93 | 3.73 | −48.3% |
| Nov 6, 2025 | 3.67 | 3.38 | +8.6% |
| Jul 31, 2025 | 3.73 | 3.36 | +11.0% |
| May 1, 2025 | 2.91 | 2.88 | +1.0% |
| Feb 27, 2025 | 3.89 | 3.86 | +0.8% |
| Oct 31, 2024 | 3.49 | 3.38 | +3.3% |
| Aug 1, 2024 | 3.42 | 3.33 | +2.7% |
1.0%of the share price, paid each year
On $1,000 invested$10a year at today's yield, before tax
+0.0%2020 to 2025
Raised–not every year
Paid per share, each year
$1.36 in 2015 → $1.36 in 2025
How safe it looks
-6.0% of its profit
Room to growStretchedMore than it earns: 24.6%
News
Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and TeleflexYahoo Finance · Sep 29, 20263 Reasons to Avoid TFX and 1 Stock to Buy InsteadYahoo Finance · Sep 28, 2026The newest story we have is from Sep 29, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
51No pass
Philip Fisher
41No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
35No pass
Terry Smith
23No pass
Questions about Teleflex
Is Teleflex a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Teleflex AI analysis
What does Teleflex do?
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It is in Medical - Instruments & Supplies, based in Wayne, PA, United States, with 15,500 employees.
Does Teleflex pay a dividend?
Yes. At today's price the dividend is 1.0% a year. In 2025 it paid out $60.3 million in dividends.
Is Teleflex stock halal?
No. Teleflex does not pass our halal screen: its debt is 44% of its market value, at or above the 33% limit. How we check
How has Teleflex stock done over the past year?
Up 41.7% over the past twelve months, to $155.10. It traded between $100.34 and $156.33, close to its high.
Who are Teleflex's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Teleflex's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.